After a long, hard slog to the clinic, stem cell player ViaCyte fuels up with $105M for its next big attack on diabetes
Over the 14 years since 3 companies merged together to create the stem cell player we now call ViaCyte in San Diego, the biotech has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
